Allergy is the most common chronic disease with 150 million people affected in Europe1, and more than 50 million2 people each year in the USA. Allergic reactions can be mild, but can also be extremely debilitating and even fatal.
We are applying ImplaVax® to this non-traditional vaccine application and develop solid dose formulations of existing and new allergy vaccines to address these challenges at a large scale.
1. European Academy of Allergy and Clinical Immunology (EAACI), Tackling the Allergy Crisis in Europe – Concerted Policy Action Needed
2. CDC (2018), Gateway to Health Communication and Social Marketing Practice. Allergies.
Enesi and Sementis are collaborating to develop and evaluate a solid dose version of Sementis’ lead peanut hypoallergy vaccine, which has the potential to offer a permanent cure for peanut allergy.
Serious allergies to peanuts represent a large unmet medical need across the world, with a high cost to healthcare systems. An ImplaVax®-enabled vaccine could provide a simple and effective means to address peanut allergy on a large scale, particularly for younger sufferers who may have an aversion to needles and traditional injections.